Ventyx Biosciences

VTYX

Market cap $559M

Strengthening our Advisory Board with addition of Mark McKenna as Strategic Advisor and Peter Libby, MD as a Clinical Advisor Expanding the Phase 2 recurrent pericarditis study into Canada, EU and the UK to evaluate QD dose ranging in preparation for the global Phase 3 development plan Interim analysis for the ongoing Phase 2 recurrent pericarditis study to now be presented as part of Ventyx's R&D Day planned for Q1 2026 SAN DIEGO, Dec. 02, 2025 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”, “Company”), a clinical-stage biopharmaceutical company focused on developing innovative oral therapies for patients with inflammation-mediated cardiovascular and neurodegenerative diseases, today announced that the Company added two leading experts to their advisory board and provided an update to its ongoing Phase 2 study of VTX2735 in patients with recurrent pericarditis (“RP”). “We are fortunate to attract such an outstanding group of scientists, clinicians and strategic advisors to work with us.

SAN DIEGO, Dec. 01, 2025 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”, “Company”), a clinical-stage biopharmaceutical company focused on developing innovative oral therapies for patients with inflammation-mediated cardiovascular and neurodegenerative diseases, today announced that Company executives will participate in a fireside chat at the upcoming Piper Sandler 37th Annual Healthcare Conference in New York.

Ventyx Biosciences stock jumps 156% as its mid-stage obesity and CV risk study achieves key safety, tolerability, anti-inflammatory and CV risk reduction goals.

SAN DIEGO, Nov. 17, 2025 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”, “Company”), a clinical-stage biopharmaceutical company focused on developing innovative oral therapies for patients with inflammation-mediated cardiovascular and neurodegenerative diseases, today announced that Company executives will participate in a fireside chat at the upcoming Jefferies Global Healthcare Conference in London.

Data from the recent Phase 2 study position Ventyx's NLRP3 inhibitor VTX3232 as a next generation, oral anti-inflammatory therapy, for cardiovascular disease Positive topline data from Phase 2a biomarker trial support the potential use of VTX3232 as a disease-modifying therapy for patients with Parkinson's disease Topline data from Phase 2 study of VTX2735 in patients with recurrent pericarditis expected in Q4 2025 Cash, cash equivalents and marketable securities balance of $192.6M as of September 30, 2025, expected to fund planned operations into at least H2 2026 SAN DIEGO, Nov. 06, 2025 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”, “Company”), a clinical-stage biopharmaceutical company focused on developing innovative oral therapies for patients with autoimmune, inflammatory, and neurodegenerative diseases, today reported third quarter financial results and highlighted recent pipeline and business progress. “I am proud of the Ventyx team for achieving two key milestones this year, generating data from the Phase 2a study with our CNS penetrant NLRP3 inhibitor VTX3232 in patients with early Parkinson's disease and, more recently, data from the VTX3232 Phase 2 study in participants with obesity and cardiovascular risk factors.

Ventyx Biosciences, Inc. (NASDAQ:VTYX ) Discusses Positive Phase II Results of VTX3232 in Obesity and Cardiovascular Risk Factors October 22, 2025 4:30 PM EDT Company Participants Alex Schwartz Raju Mohan - Founder, CEO, President & Director Mark Forman Roy Gonzales - Senior VP of Finance and Principal Financial & Accounting Officer Conference Call Participants Antonio Abbate Peter Libby Lin Tsai - Jefferies LLC, Research Division Samuel Slutsky - LifeSci Capital, LLC, Research Division Yasmeen Rahimi - Piper Sandler & Co., Research Division Derek Archila - Wells Fargo Securities, LLC, Research Division Jeffrey Jones - Oppenheimer & Co. Inc., Research Division Alexander Thompson - Stifel, Nicolaus & Company, Incorporated, Research Division Presentation Operator Good day, everyone, and welcome to today's Ventyx business update call. [Operator Instructions] Today's call is being recorded.

VTX3232 demonstrated significant reductions in cardiovascular risk factors, with additional benefits when combined with semaglutide VTX3232 monotherapy achieved ~80% reduction in hsCRP within the first week VTX3232 monotherapy reduced IL-6 levels at Week 12 below the threshold for cardiovascular risk of ≤1.65ng/L 1 Statistically significant reductions in Lp(a) and liver inflammation No effect on weight either as a monotherapy or as add-on to semaglutide VTX3232 was safe and well tolerated both as a monotherapy and add-on to semaglutide in this study Ventyx to hold conference call and webcast 4:30pm ET on Wednesday, October 22nd SAN DIEGO, Oct. 22, 2025 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”, “Company”), today announced positive results from its Phase 2 study of oral, once-daily VTX3232 in patients with Obesity and Cardiovascular Risk Factors. The 175- participant study examined VTX3232 versus placebo, alone or in combination with semaglutide, evaluating safety and tolerability as the primary endpoint, and effects on inflammation (measured by high-sensitivity C-reactive protein or hsCRP) as the secondary endpoint.

Does Ventyx Biosciences, Inc. (VTYX) have what it takes to be a top stock pick for momentum investors? Let's find out.

SAN DIEGO, Aug. 27, 2025 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”, “Company”), a clinical-stage biopharmaceutical company focused on developing innovative oral therapies for patients with autoimmune, inflammatory, and neurodegenerative diseases, today announced that Company executives will participate in the following upcoming investor conferences: 2025 Wells Fargo Healthcare Conference Location: Boston, MADate: Friday, September 5, 2025Time: 11:00-11:35 AM EDT Morgan Stanley 23 rd Annual Global Healthcare Conference Location: New York, NYDate: Monday, September 8, 2025 H.C. Wainwright 27th Annual Global Investment Conference Location: New York, NYDate: Monday, September 8, 2025 A webcast of the Wells Fargo presentation will be available in the Investors and News section of the Ventyx website at  www.ventyxbio.com.

Ventyx Biosciences (VTYX -6.72%), a clinical-stage biopharmaceutical company focused on developing treatments for inflammatory and neurodegenerative diseases, released its second-quarter 2025 results on August 7, 2025. EPS (GAAP) was $0.38, which exceeded the analyst consensus estimate of $(0.47) GAAP.